Advancing the next generation of cancer treatment with circular RNAs in CAR-T cell therapy

Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 181, P. 117753 - 117753

Published: Dec. 1, 2024

Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematological malignancies. However, its effectiveness against solid tumors remains constrained by challenges such as exhaustion, limited persistence, and off-target effects. These highlight critical gaps in current CAR-T cell therapeutic strategies, particularly for tumor applications. Circular RNAs (circRNAs) represent a transformative class non-coding RNAs, known their exceptional stability precise regulatory functions, positioning them promising candidates enhancing next-generation therapies. Notably, circRNAs can bridge gap between preclinical research clinical application offering innovative solutions to overcome technical hurdles improve outcomes. Despite potential, remain underexplored therapies tumors, presenting significant opportunity innovation. The mechanisms through which modulate specificity are not yet fully understood, challenges, achieving efficient targeted circRNA delivery, still need be addressed. This review highlights importance integrating into enhance specificity, minimize effects, durability. By emphasizing potential identifying key gaps, this provides roadmap advancing setting stage next generation personalized cancer treatments.

Language: Английский

RNA Delivery Nanoparticles for Infectious Diseases

Materials chemistry horizons., Journal Year: 2024, Volume and Issue: 3(3), P. 1 - 14

Published: Dec. 1, 2024

Language: Английский